In this study, we attempt to look at the various presentations, comorbidities and association of the recent epidemic of rhino-orbital cerebral mucormycosis with Covid-19 in central India. A prospective study of 612 patients diagnosed with mucormycosis from April to July 2021. Detailed history was taken and thorough clinical examination was done. The relation of mucormycosis with Covid-19 and other morbidities was studied. Nasal endoscopy, imaging and management findings were tabulated and analyzed. Male predominance of the disease was noted. The most common age group affected was found to be 41-50 years group having 33.1% of all patients. 83.2% patients had history of Covid-19 infection. Majority of the patients (41.6%) had mucormycosis symptoms within 1 month of Covid-19 symptom onset. Nasal symptoms predominated with 61.1% patients having one or more of the several nasal symptoms. Most common comorbidity was diabetes mellitus (75.8% cases). Nasal and sinus debridement was performed in 584 patients (95.4%). Mucormycosis turned into a widespread epidemic during the second wave of Covid-19 in India. Diabetes mellitus was the most common associated comorbidity that increased the risk of mucormycosis in patients with history of Covid-19 infection. A high index of suspicion in patients presenting with early symptoms in the context of Covid-19, along with prompt diagnosis using radiological, endoscopic and microbiological tools will help reduce mortality to a great extent. Mainstay of treatment is aggressive surgical and medical management, controlling comorbidities and adequate post-operative care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646106 | PMC |
http://dx.doi.org/10.1007/s12070-023-04014-7 | DOI Listing |
Cureus
December 2024
Department of Medicine, Government Medical College and Hospital, Nagpur, IND.
Background The COVID-19 pandemic has posed unprecedented challenges to the global healthcare system. Among the various complications, mucormycosis, a fungal infection caused by the Mucorales order, has emerged as a significant threat, particularly in immunocompromised individuals. This study aims to evaluate the outcomes of mucormycosis in COVID-19 patients treated at a tertiary care hospital in Central India.
View Article and Find Full Text PDFWorld J Radiol
December 2024
Department of Biostatistics, All India Institute of Medical Sciences, New Delhi 110029, India.
Background: Invasive fungal sinusitis (IFS) can present as a mild disease to life-threatening infection. A recent surge in cases was seen due to the coronavirus disease 2019 (COVID-19) pandemic. Many patients require surgical debridement and hence imaging [contrast-enhanced computed tomography (CECT) of the paranasal sinuses (PNS)] to document the extent of the disease.
View Article and Find Full Text PDFIntroduction Mucormycosis is an uncommon fungal infection caused by filamentous fungi of the Mucorales order, namely Rhizopus, Lichthemia, andMucor species. The incidence and prevalence of mucormycosis reached an all-time high during the COVID-19 pandemic due to excessive steroid use and other factors, leading to the coining of the term CAM (COVID Associated Mucormycosis). The diagnosis of mucormycosis is by a combination of histopathology and microbiological techniques, such as KOH mount and culture.
View Article and Find Full Text PDFJ Family Med Prim Care
December 2024
Department of Oral Medicine and Radiology, Post Graduate Institute of Dental Sciences Rohtak, Haryana, India.
Introduction: Association of mask-wearing habit and mucormycosis.
Context: During the second wave of the COVID-19 pandemic, there was an absurd surge in cases of mucormycosis. COVID-19-associated mucormycosis (CAM) was found to be associated with the presence of diabetes, use of systemic steroids, prolonged use of masks, and others.
Arch Craniofac Surg
December 2024
Department of Dentistry, All India Institute of Medical Sciences Bhopal, Bhopal, India.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!